Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Diamedica Therapeutics ( (DMAC) ) is now available.
DiaMedica Therapeutics announced its financial results for 2024, highlighting significant progress in its acute ischemic stroke (AIS) program and expansion into preeclampsia treatment. The company is advancing its Phase 2 trial for preeclampsia and ongoing enrollment for its Phase 2/3 AIS program. Additionally, DiaMedica appointed Daniel J. O’Connor to its board, and it has secured a cash runway into the third quarter of 2026, positioning itself strongly in the biopharmaceutical industry.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia. The company aims to address substantial unmet medical needs in these critically underserved populations, presenting large commercial opportunities.
YTD Price Performance: 4.72%
Average Trading Volume: 87,293
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $246.7M
Find detailed analytics on DMAC stock on TipRanks’ Stock Analysis page.